Similarly, we identified proteins with known relevance to RCC like AXL, a target of cabozantinib, effective treatment for RCC77,78, and FBP1, a metabolic regulator frequently affected in clear cell RCC (ccRCC)66, highlighting how disrupted TF activity may drive downstream protein levels and oncogenic processes. This evidence concerns the gene FBP1 and renal cell carcinoma.